Next Article in Journal / Special Issue
New Tools for Molecular Therapy of Hepatocellular Carcinoma
Previous Article in Journal / Special Issue
Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma
Article Menu

Export Article

Open AccessReview
Diseases 2015, 3(4), 306-324; doi:10.3390/diseases3040306

Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma

Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Stephen L. Chan
Received: 28 August 2015 / Revised: 4 October 2015 / Accepted: 21 October 2015 / Published: 28 October 2015
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
View Full-Text   |   Download PDF [886 KB, uploaded 28 October 2015]   |  

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death. In patients with advanced or unresectable HCC, there are few treatment options. Conventional chemotherapy has limited benefits. Sorafenib, a multi-kinase inhibitor, improves survival, but options for patients intolerant of or progressing on sorafenib are limited. There has been much interest in recent years in molecular therapeutic targets and drug development for HCC. One of the more promising molecular targets in HCC is the cellular-mesenchymal-epithelial transition (c-MET) factor receptor. Encouraging phase II data on two c-MET inhibitors, tivantinib and cabozantinib, has led to phase III trials. This review describes the c-MET/hepatocyte growth factor (HGF) signalling pathway and its relevance to HCC, and discusses the preclinical and clinical trial data for inhibitors of this pathway in HCC. View Full-Text
Keywords: hepatocellular carcinoma (HCC); c-MET; hepatocyte growth factor (HGF); c-MET inhibitor; tivantinib; cabozantinib hepatocellular carcinoma (HCC); c-MET; hepatocyte growth factor (HGF); c-MET inhibitor; tivantinib; cabozantinib
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Lee, J.J.X.; Chan, J.J.; Choo, S.P. Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma. Diseases 2015, 3, 306-324.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top